VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
CHRN
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
CHRNChronoScale Corporation
$9.39$38M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksCHRNFinancials

ChronoScale Corporation (CHRN) Income Statement

13Y historyFree accessUpdated daily

Revenue momentum has deteriorated significantly, evidenced by a 36.6% year-over-year decline in 2026Q1 and an unsustainable operating margin of -2.6% despite a 50.2% gross margin.

Income StatementBalance SheetCash FlowRatios

CHRN Income Statement

Annual statement

CHRN Income Statement

ChronoScale Corporation (CHRN) annual income statement — 13-year revenue, gross profit & net income history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13
Sales/Revenue11.56M12.8M17.93M18.28M12.91M11.25M8.88M13.92M11.33M7.35M14.22M8.66M5.33M3.3M
Revenue Growth %-34.08%-28.6%-1.94%41.57%14.81%26.62%-36.18%22.81%54.11%-48.29%64.2%62.59%61.33%-
Cost of Goods Sold49.84M5.95M8.41M9.2M6.7M4.5M3.81M7.15M7.02M5.28M11.27M7.48M3.77M2.71M
COGS % of Revenue-46.52%46.94%50.33%51.87%39.99%42.92%51.4%61.97%71.86%79.28%86.39%70.73%82.22%
Gross Profit6.11M6.84M9.51M9.08M6.21M6.75M5.07M6.76M4.31M2.07M2.95M1.18M1.56M587K
Gross Margin %52.86%53.48%53.06%49.67%48.13%60.01%57.08%48.6%38.03%28.14%20.72%13.61%29.27%17.78%
Gross Profit Growth %--28.03%4.76%46.11%-7.93%33.12%-25.04%56.97%108.26%-29.79%149.96%-24.37%165.59%-
Operating Expenses37.56M20.17M19.97M24.19M21.77M20.58M17.93M23.4M31.37M33.35M30.73M22.74M18.35M11.44K
OpEx % of Revenue-157.6%111.41%132.34%168.6%182.97%201.85%168.16%276.86%453.61%216.08%262.56%344.53%0.35%
Selling, General & Admin35.79M17.14M16.1M19.17M18.14M17.83M15.45M18.81M25.53M23.87M21.85M16.26M14.48M10.94K
SG&A % of Revenue-133.92%89.8%104.85%140.52%158.54%173.99%135.14%225.26%324.64%153.65%187.74%271.92%0.33%
Research & Development1.77M3.03M3.87M5.03M3.63M2.75M2.47M4.6M5.85M9.48M8.88M6.48M3.87M3.93M
R&D % of Revenue-23.68%21.61%27.49%28.08%24.44%27.85%33.02%51.6%128.97%62.44%74.82%72.61%119.05%
Other Operating Expenses000000000296K-166K-45K-61K500
Operating Income-15.5M-13.33M-10.46M-15.11M-15.56M-13.83M-12.86M-16.64M-27.03M-31.61M-27.59M-21.56M-16.79M-12.29K
Operating Margin %-134.06%-104.12%-58.35%-82.67%-120.48%-122.96%-144.76%-119.56%-238.53%-429.92%-193.98%-248.94%-315.26%-0.37%
Operating Income Growth %--27.4%30.78%2.85%-12.5%-7.54%22.72%38.44%14.49%-14.59%-27.94%-28.39%-136525.45%-
EBITDA-13.86M-11.75M-8.85M-13.41M-14.67M-13.27M-12.24M-15.95M-25.53M-29.88M-25.73M-20.63M-16.05M-10.9K
EBITDA Margin %-119.8%-91.83%-49.38%-73.38%-113.61%-117.97%-137.78%-114.6%-225.29%-406.36%-180.94%-238.17%-301.28%-0.33%
EBITDA Growth %-52.86%-32.77%34.01%8.56%-10.57%-8.41%23.27%37.53%14.56%-16.12%-24.74%-28.53%-147138.53%-
D&A (Non-Cash Add-back)16.61M1.57M1.61M1.7M887K561K620K690K1.5M1.73M1.85M933K745K1.39K
EBIT-37.22M-11.39M-11.06M-14.9M-14.92M-9.65M-15.69M-11.75M-26.39M-28.47M-23.45M-19.58M-33.33M-10.96M
Net Interest Income-690K-309K-269K-302K-156K-113K-139K-1.48M-600K-648K-4K-2K-429K0
Interest Income0000000384K0012K11K6K0
Interest Expense2.19M309K269K302K156K113K139K384K600K648K16K13K435K0
Other Income/Expense-2.99M1.63M-870K-86K476K4.06M-2.97M4.51M38K2.49M4.12M1.97M-16.98M-1.59M
Pretax Income-39.41M-11.7M-11.33M-15.2M-15.08M-9.76M-15.82M-12.13M-26.99M-29.12M-23.47M-19.59M-33.77M-12.29K
Pretax Margin %-340.77%-91.37%-63.21%-83.14%-116.79%-86.82%-178.17%-87.17%-238.19%-396.06%-165.04%-226.19%-633.92%-0.37%
Income Tax0000000000000-541
Effective Tax Rate %0%0%0%0%0%0%0%0%0%0%0%0%0%4.4%
Net Income-15.69M-11.7M-11.33M-15.2M-15.08M-9.76M-15.82M-12.13M-26.99M-29.12M-23.47M-19.59M-33.77M-12.29K
Net Margin %-135.66%-91.37%-63.21%-83.14%-116.79%-86.82%-178.17%-87.17%-238.19%-396.06%-165.04%-226.19%-633.92%-0.37%
Net Income Growth %-45.38%-3.22%25.45%-0.78%-54.44%38.3%-30.44%55.05%7.31%-24.08%-19.81%41.99%-274623.4%-
Net Income (Continuing)-39.41M-11.7M-11.33M-15.2M-15.08M-9.76M-15.82M-12.13M-26.99M-29.12M-23.47M-19.59M-33.77M-11.89M
Discontinued Operations-1000K0000000000000
Minority Interest00000000000000
EPS (Diluted)-4.40-4.91-8.43-16.44-17.45-13.20-33.13-37.96-99.19-184.01-419.75-373.50-677.25-237.82
EPS Growth %26.27%41.76%48.72%5.79%-32.2%60.16%12.72%61.73%46.1%56.16%-12.38%44.85%-184.77%-
EPS (Basic)--4.91-8.43-16.44-17.45-12.01-33.13-37.96-99.19-184.01-419.75-373.50-677.25-237.82
Diluted Shares Outstanding145.41M2.43M1.34M924.47K864.13K817.93K477.6K319.6K272.13K158.26K80.56K64.91K49.69K49.83K
Basic Shares Outstanding145.41M2.43M1.34M924.47K864.13K812.87K477.6K319.6K272.13K158.26K80.56K64.91K49.69K49.83K
Dividend Payout Ratio--------------

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and solvency crisis

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Revenue Momentum Facing Severe Contraction

As reported in recent financial filings, Ekso Bionics experienced a significant 36.6% year-over-year revenue decline in 2026Q1, signaling a sharp deterioration in market demand that suggests the company's current commercial strategy is failing to gain traction within the competitive medical exoskeleton landscape for institutional rehabilitation facilities.

The consistent pattern of negative revenue growth over the last several quarters indicates that the company is struggling to convert its clinical value proposition into reliable capital equipment sales. This trend suggests that hospital procurement cycles are increasingly excluding the EksoNR platform, potentially due to budget constraints or a lack of clear reimbursement pathways.

Operating Leverage Remains Fundamentally Absent

Based on the company's reported figures, the operating margin of -104.12% highlights a profound inability to scale revenue against fixed overhead, as SG&A expenses continue to dwarf gross profit, leaving the firm without the necessary operating leverage to achieve a path toward sustainable profitability.

The persistent gap between gross profit and operating expenses suggests that the current cost structure is misaligned with the company's actual sales volume. Investors should monitor whether management can implement meaningful cost-cutting measures, as the current burn rate appears to be structurally embedded in the business model.

High Fixed Costs Constrain Viability

According to recent SEC filings, Ekso's cost structure is heavily burdened by high SG&A requirements, which consistently exceed gross profit, indicating that the company's reliance on a specialized, high-touch sales force is currently unsustainable given the prevailing weakness in top-line revenue generation and unit growth.

The company's inability to reduce SG&A in proportion to declining revenue suggests a lack of expense discipline or a requirement for high-cost clinical support that cannot be easily scaled down. This cost rigidity may force the company into further dilutive financing to maintain operations.

Structural Risks to Going Concern

Based on the provided income statement data, the combination of a -104% operating margin and critically low cash reserves suggests that the company faces an existential risk, as the current trajectory of losses appears to outpace the firm's ability to generate sufficient cash from operations.

Short-sellers would likely focus on the widening gap between cash burn and revenue, which implies that the company may be nearing a point where it can no longer fund its R&D and sales efforts. The lack of a clear inflection point in the data warrants extreme caution regarding the company's long-term solvency.

CHRN — Frequently Asked Questions

Quick answers to the most common questions about buying CHRN stock.

What was ChronoScale Corporation's (CHRN) revenue in 2025?

For fiscal year 2025, ChronoScale Corporation (CHRN) reported total revenue of $12.8M. This represents a 287.6% increase compared to $3.3M in 2013.

Is ChronoScale Corporation (CHRN) profitable?

ChronoScale Corporation (CHRN) reported a net loss of $11.7M for the fiscal year ending 2025.

What is ChronoScale Corporation's operating profit margin?

ChronoScale Corporation (CHRN) reported an operating income of $-13.3M, resulting in an operating profit margin of -104.1%. This margin reflects the operational efficiency of the business before interest and taxes.

What is ChronoScale Corporation's gross profit and gross margin?

ChronoScale Corporation (CHRN) generated $6.8M in gross profit for the year, representing a gross profit margin of 53.5%. This demonstrates the company's core pricing power and production efficiency.